ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 275 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 2.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $14,208,000 | +221.9% | 265,772 | +148.4% | 0.12% | +125.5% |
| Q3 2020 | $4,414,000 | +7.3% | 107,000 | +11.3% | 0.06% | -6.8% |
| Q4 2019 | $4,113,000 | +18.9% | 96,143 | 0.0% | 0.06% | -10.6% |
| Q3 2019 | $3,460,000 | +27.0% | 96,143 | -5.6% | 0.07% | +57.1% |
| Q2 2019 | $2,724,000 | -95.8% | 101,900 | -97.6% | 0.04% | -94.6% |
| Q2 2018 | $65,392,000 | -12.9% | 4,282,400 | +28.2% | 0.78% | -16.2% |
| Q1 2018 | $75,066,000 | +193.6% | 3,340,700 | +293.4% | 0.93% | +188.2% |
| Q4 2017 | $25,566,000 | -36.4% | 849,100 | -27.4% | 0.32% | -29.2% |
| Q1 2017 | $40,190,000 | +2.6% | 1,169,000 | -16.6% | 0.46% | +10.7% |
| Q1 2016 | $39,189,000 | +1061.5% | 1,401,600 | +938.2% | 0.41% | +724.0% |
| Q4 2013 | $3,374,000 | -60.6% | 135,000 | -56.7% | 0.05% | -67.3% |
| Q3 2013 | $8,571,000 | -63.5% | 312,000 | -75.9% | 0.15% | -69.2% |
| Q2 2013 | $23,468,000 | – | 1,293,000 | – | 0.50% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |